Branched‐chain keto‐acid dehydrogenase kinase regulates vascular permeability and angiogenesis to facilitate tumor metastasis in renal cell carcinoma
Cancer Science · 2023
DOI: 10.1111/cas.15956 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2023. Verfasst von Kunao Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, MicroRNAs. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, The Scientific Research Foundation for Advanced Talents, Xiang'an Hospital of Xiamen University.
Abstract (Originalsprache)
Branched‐chain keto‐acid dehydrogenase kinase (BCKDK) is the rate‐limiting enzyme of branched‐chain amino acid (BCAA) metabolism. In the last six years, BCKDK has been used as a kinase to promote tumor proliferation and metastasis. Renal cell carcinoma (RCC) is a highly vascularized tumor. A high degree of vascularization promotes tumor metastasis. Our objective is to explore the relationship between BCKDK and RCC metastasis and its specific mechanism. In our study, BCKDK is highly expressed in renal clear cell carcinoma and promotes the migration of clear cell renal cell carcinoma (ccRCC). Exosomes from ccRCC cells can promote vascular permeability and angiogenesis, especially when BCKDK is overexpressed in ccRCC cells. BCKDK can also augment the miR‐125a‐5p expression in ccRCC cells and derived exosomes, thereby decreasing the downstream target protein VE‐cadherin level, weakening adhesion junction expression, increasing vascular permeability, and promoting angiogenesis in HUVECs. The novel BCKDK/Exosome‐miR‐125a‐5p/VE‐cadherin axis regulates intercellular communication between ccRCC cells and HUVECs. BCKDK plays a critical role in renal cancer metastasis, may be used as a molecular marker of metastatic ccRCC, and even may become a potential target of clinical anti‐vascular therapy for ccRCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
- Department of Tumor, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
- Central Laboratory, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
ORCID-Profile: Chen Shao
Förderung
- National Natural Science Foundation of China
- The Scientific Research Foundation for Advanced Talents, Xiang'an Hospital of Xiamen University
Zitieren
APA
Yang, K., Xu, C., Sun, H., Xuan, Z., Liu, Y., Li, J., Bai, Y., Zheng, Z., Zhao, Y., Shi, Z., Zheng, J., & Shao, C. (2023). Branched‐chain keto‐acid dehydrogenase kinase regulates vascular permeability and angiogenesis to facilitate tumor metastasis in renal cell carcinoma. Cancer Science. https://doi.org/10.1111/cas.15956
Vancouver
Yang K, Xu C, Sun H, Xuan Z, Liu Y, Li J, et al. Branched‐chain keto‐acid dehydrogenase kinase regulates vascular permeability and angiogenesis to facilitate tumor metastasis in renal cell carcinoma. Cancer Science. 2023. doi:10.1111/cas.15956
BibTeX
@article{Yang2023,
author = {Yang, Kunao and Xu, Chunlan and Sun, Huimin and Xuan, Zuodong and Liu, Yankuo and Li, Jinxin and Bai, Yang and Zheng, Zeyuan and Zhao, Yue and Shi, Zhiyuan and Zheng, Jianzhong and Shao, Chen},
title = {Branched‐chain keto‐acid dehydrogenase kinase regulates vascular permeability and angiogenesis to facilitate tumor metastasis in renal cell carcinoma},
journal = {Cancer Science},
year = {2023},
doi = {10.1111/cas.15956}
}
EUVIMED